Bone marrow cells of 82 patients with multiple myeloma were subjected to flow cytometric analysis of DNA and cytoplasmic immunoglobulin (CIg) content using propidium iodide and direct immunofluorescence assays. Except for two patients with nonsecretory myeloma, there was conformity in the immunoglobulin type derived from immunoelectrophoresis and plasma cell CIg staining. One patient with nonsecretory myeloma exhibited monotypic CIg staining, while the second showed no reaction. In eight patients with IgG lambda myeloma, the same tumor cells contained both lambda and kappa light chains, suggesting the productive rearrangement of both light chain genes. 14 patients with previously unrecognized plasma cells of low RNA content, all of whom were resistant to chemotherapy, were identified by CIg staining. By revealing previously unrecognized plasma cells with low RNA content, CIg analysis identified more patients with treatmentrefractory myeloma.
Introduction
The plasma cells of patients with multiple myeloma usually contain an abnormal DNA and an increased RNA content, permitting the quantitation of plasma cells by flow cytometry (1-3). Higher response rates to both initial and salvage therapy have been noted with increasing RNA content (4, 5) , and a shorter survival time has been found in patients with marked bone marrow plasmacytosis (4) . A typical feature of plasma cells is the presence of cytoplasmic immunoglobulin (CIg). ' We have developed a flow cytometric assay for the concurrent analysis of DNA and CIg content in order to quantify plasma cells when studies of DNA and RNA content could not provide a clear distinction from normal cells. Whether CIg staining might clarify the biology of plasma cells in patients with nonsecretory disease or with other atypical clinical features was also evaluated. patients contained at least 7% plasma cells on routine morphological examination. For flow cytometry studies, bone marrow aspirates were separated by Hypaque-Ficoll gradient centrifugation (6) . Interphase cells were collected and washed once in phosphate-buffered saline. One aliquot of cells was always stained with the metachromatic dye acridine orange for concomitant DNA and RNA analysis using a mercury arc flow cytometer (Phywe Co., Gottingen, Germany) (7) . Routinely, 10,000 cells were analyzed and tumor cells gated on the basis of abnormal DNA and RNA content (1, 4) . In this manner, tumor cell DNA and RNA index values were derived from the relation to normal lymphocytes (specifically, the ratio of median fluorescence channel numbers of tumor to normal diploid cells) (1) . The proportion of cells with abnormal DNA and/or RNA content in the entire sample was also determined.
A second bone marrow aliquot was processed for biparametric DNA-CIg analysis with an EPICS V flow sorter (Coulter Electronics, Inc., Hialeah, FL). Cells were fixed in 70% ice-cold ethanol for at least 24 h. Single cell suspensions were then exposed separately to antilight-chain and anti-heavy-chain reagents (fluorescein-conjugated F(ab')2 fragments; Capell Laboratories, Westchester, PA) at dilutions of 1:200 (0.1 mg/ml) and counterstained for DNA with propidium iodide (8) . In three instances of dual light chain reaction, different antisera were evaluated in the same manner (Tago Inc., Burlingame, CA).
Successive flow cytometric analyses were performed on 10,000 cells, each stained for both light chains, and, in a subset of patients, stained also for two heavy chains (typically, IgG and IgA). Except for eight instances of dual light chain reaction, marked differences in staining intensity were observed between pairs of samples stained for light and heavy chains (see Fig. 1 ). In the "80% of patients with DNA-abnormal stemlines, bright CIg fluorescence was usually limited to aneuploid cells, while residual diploid cells showed the same dim fluorescence observed after staining with the opposite light chain reagent. The proportion of tumor cells was readily determined by applying an electronic gating procedure to the brightly stained cells with an abnormal DNA content (Fig. 1) . To obtain a measure of CIg content for each patient, a CIg index was computed from the ratio of median CIg fluorescence intensities of aneuploid and diploid GI cells of the same sample.
For the remaining DNA-diploid samples, both the percentage of plasma cells and their CIg index were determined in comparison with the nonspecific staining pattern of cells reacted with the opposite light chain antiserum. Specifically, kappa and lambda distribution curves were superimposed electronically to identify the lower level of specific CIg fluorescence. The CIg index was then computed from the ratio of median intensities of specific and nonspecific (opposite light chain) fluorescence. The degree ofheterogeneity of CIg content among plasma cells from the same patient was expressed as a coefficient of variation (CV) ofthe monotypic CIg distribution. The CV (percent) was computed from the ratio of the standard deviation and the mean of CIg fluorescence channel numbers times 100.
There were eight patients with dual cytoplasmic light chain expres- 18 patients on whom additional heavy chain analyses were conducted. Two patients lacked a monoclonal protein by immunoelectrophoresis, but showed marrow involvement microscopically (25 and 42%) and by DNA-RNA flow cytometry (18 and 69%). One patient had kappa staining within the cytoplasm ("low secretor"), while the second showed no detectable anti-light-chain reaction ("low producer"). A third (Fig. 3 A) . Among the 29 patients with diploid myeloma, there were 8 patients with a DNA-RNA pattern indistinguishable from normal marrow but a monoclonal light chain reaction was evident in 5-69% of cells (median, 26%).
These cells corresponded to plasma cells on microscopic examination (Fig. 3 B) . One patient with nonsecretory myeloma showed 60-70% plasma cells with high RNA content but lacked a monotypic CIg pattern ("low-producing myeloma"). There were also 6 patients with aneuploid myeloma, in whom a second diploid DNA stemline with 5-20% plasma cells was uncovered by monotypic CIg staining (four kappa and two lambda) (Fig. 4) . ThUs, the combined analysis of DNA-CIg and DNA-RNA permitted the identification of previously unrecognized cell populations with low RNA content in -20% of our patients.
Eight patients with a discrete DNA-RNA abnormality had plasma cells which expressed both kappa and lambda light chains. Immunoelectrophoresis revealed monoclonal IgG lambda in all instances. An example of such double-staining is illustrated in Fig. 5 with three different DNA stemlines in the diploid, the low degree hyperdiploid, and the tetraploid range, all of which expressed kappa, lambda, and IgG immunoglobulin (the latter not shown). Fluorescence microscopy revealed concurrent kappa and lambda reactions in the same plasma cells. The dual light chain reaction was confirmed in three patients using a different source of anti-light-chain antisera.
There was marked variation in the CIg staining per plasma cell in individual patients, which was expressed as a CV ranging from 30 to 80% (median, 50%). To compare the CIg content per cell among different patients, a CIg index was defined from the ratio of the median fluorescence intensities of specific vs. nonspecific anti-light-chain reactions. Among 23 patients studied at diagnosis, the CIg index ranged from 2 to 27, with a median value of 10. There was no correlation between the RNA and the CIg index, but the CIg index decreased with increasing marrow tumor infiltrate (R = -0.25, P < 0.01).
We As we had noted with RNA content, the CIg content per plasma cell varied markedly within and among patients. In previously untreated patients, increasing bone marrow plasmacytosis was associated with a decrease in CIg index and RNA index (18) , which might reflect less differentiated and perhaps more aggressive features of myeloma. The resistance to chemotherapy of low RNA index myeloma has been established (4, 5, 17) and may be related in part to a greater degree of RNA heterogeneity with increasing tumor burden (18, 19) . Similar inferences cannot yet be made for CIg index and CIg dispersion in view of the small number of patients evaluated at diagnosis.
In summary, DNA-CIg flow cytometry aids in several aspects of myeloma research and clinical management. We were able to recognize patients with "low-secretory" and "lowproducing" disease. The biological significance of CIg dispersion and the coexpression by the same tumor cell of both light chains requires further study. The importance of objective and quantitative assessment of the degree of marrow tumor infiltration has been demonstrated (4, 17) . DNA-CIg analysis is superior to DNA-RNA cytometry for assessing marrow plasmacytosis because monoclonal CIg is more specific for abnormal plasma cells. In conjunction with DNA-RNA flow cytometry, CIg analysis permitted the identification of more patients with a poor prognosis, whose plasma cells either had a low RNA content, biclonal DNA abnormalities, or both.
